<div><div></div><div><span><p><span>Aprea Therapeutics, Inc. reported first-quarter 2026 results showing no revenue and a narrower net loss versus the year-ago quarter. The company recorded revenue of $0 and a net loss of $(3.29M) for Q1 2026, with diluted loss per share of $(0.22), an improvement versus the prior-year quarter.</span></p><p><strong><span>Financial Highlights</span></strong></p><ul><li><span>Revenue was $0 for Q1 2026, down from $162,463 in Q1 2025 (‑$162.5K YoY).</span></li><li><span>Net income was a net loss of $(3.29M) for Q1 2026, improved from a net loss of $(3.93M) in Q1 2025 (improvement of $0.64M YoY).</span></li><li><span>Diluted earnings per share was $(0.22) for Q1 2026, versus $(0.66) in Q1 2025 (improvement of $0.44 YoY).</span></li></ul><p><strong><span>Business Highlights</span></strong></p><ul><li><span>Clinical progress: APR-1051 showed early proof-of-concept with confirmed partial responses in PPP2R1A‑mutated endometrial cancer; dose escalation continues in the 300–500mg range.</span></li><li><span>Pipeline updates: ATRN‑119 completed monotherapy dose escalation with an RP2D of 1,100mg and is being evaluated in combination strategies; APR‑1602 is slated to enter IND‑enabling studies in late 2026.</span></li><li><span>Operational shift: The company is winding down ABOYA‑119 monotherapy work to prioritize ATRN‑119 combination studies and investigator‑initiated collaborations.</span></li><li><span>Development plan: The ACESOT‑1051 expansion aims to enroll at least 50 patients with uterine serous carcinoma and platinum‑resistant ovarian cancer to refine the biomarker strategy.</span></li><li><span>Balance sheet: Cash on hand is expected to fund operations into Q1 2028 following significant equity raises in private placements during Jan–Mar 2026 to support clinical development.</span></li></ul><p><span>Original SEC Filing: </span>Aprea Therapeutics, Inc. [ APRE ] - 10-Q - May. 13, 2026</p><section><b><span class="heading-aHOVUrmQ">Disclaimer</span></b><div><span>This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.</span></div></section></span></div></div>

APRE

LABU

SBIO

<p>Aprea Therapeutics, Inc. reported Q1 2026 results with $0 revenue and a net loss of $(3.29M), an improvement from $(3.93M) in Q1 2025. Diluted EPS was $(0.22), up from $(0.66) YoY. Clinical progress includes APR-1051 showing partial responses in endometrial cancer. The company is prioritizing ATRN-119 combination studies and expects cash to fund operations into Q1 2028 after recent equity raises.</p>

TradingView

Aprea Therapeutics

SPDR S&P Biotech

Invesco Biotechnology & Genome ETF

Proshares Ultra Nasdaq Biotech

iShares Biotechnology ETF

VanEck Biotech ETF

First Trust NYSE Arca Biotech Index Fd

Direxion S&P Biotech Bull 3X

ALPS Medical Breakthrough

Aprea Therapeutics, Inc. 1Q 2026: Revenue $0 EPS $(0.22) — 10-Q Summary